Life Technologies collaborated with the USDA to develop a test to detect the presence of E. coli O157:H7, and later expanded the project to include the "Big 6" non-O157 strains (O26, O45, O103, O111, O121 and O145), which cause about 70 percent of non-O157 infection.
The validated system is capable of clearing negative beef samples (375 grams), and identifying presumptive positives in the same sample run with an additional hour of testing. Its sensitivity provides greater confidence in the results since the solution can detect as little as 1 to 5 colony-forming units of pathogenic STEC in a single sample.
Life Technologies collaborated with the USDA to develop and validate RapidFinder™ and utilized Life's core competencies in DNA sample preparation, real-time PCR assay formats design, DNA sequencing and data interpretation.
RapidFinder™ STEC is for Testing of Food and Environmental Samples.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of
in 2011. Visit us at our website:
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.